Abstract
Fifty-four newly diagnosed patients with advanced Hodgkin's disease were randomized between two alternating non cross-resistant chemotherapies: MOPP-ABVD (MOPP: Mustine, Vincristine, Procarbazine, Prednisone-ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine) and MOPP-ABVD-CEM (CEM: Carmustine, Etoposide, methyl-GAG). There were no significant differences between the two therapies as far as complete remission, survival, relapse free survival and toxicity were concerned. This study does not support the use of MOPP-ABVD-CEM for improving the long-term outcome of patients with advanced Hodgkin's disease.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Carmustine / administration & dosage
-
Dacarbazine / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / mortality
-
Humans
-
Male
-
Mechlorethamine / administration & dosage
-
Mitoguazone / administration & dosage
-
Prednisone / administration & dosage
-
Procarbazine / administration & dosage
-
Prospective Studies
-
Survival Rate
-
Vinblastine
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Procarbazine
-
Mechlorethamine
-
Vincristine
-
Vinblastine
-
Etoposide
-
Dacarbazine
-
Doxorubicin
-
Mitoguazone
-
Carmustine
-
Prednisone
Supplementary concepts
-
ABVD protocol
-
MOPP protocol